News | January 31, 2026
Glenmark reports robust Q3 FY26 performance, revenues surge 15% YoY
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Fid?s brings core strengths across imaging applications and human biology, supporting work in digestive disease, GI oncology, and select solid tumors
The base Gland business posted ?11,790 million in revenue, up 16% YoY
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
EYRA features intuitive software, automation readiness, and the ability to detect dozens of analytes simultaneously with minimal hands-on time
The upcoming Phase I trial will test the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers and determine the optimal dosing for future studies
This deal marks a major step for Alteogen as it pushes its Hybrozyme platform deeper into the oncology market
The company has posted net profit of Rs. 4,064.9 crore for the 9 months period ended December 31, 2025
This marks the second indication for which gumokimab has gained NDA review acceptance
Subscribe To Our Newsletter & Stay Updated
